Krishnan Patel, MD, MHS (@krishnan_patel) 's Twitter Profile
Krishnan Patel, MD, MHS

@krishnan_patel

Academic Radiation Oncologist. All views are my own and not reflective of my employer.

ID: 737464313858789376

calendar_today31-05-2016 02:02:48

19 Tweet

122 Takipçi

104 Takip Edilen

NEJM AI (@nejm_ai) 's Twitter Profile Photo

In the most comprehensive head-to-head comparison of modern AI-based LLMs for application in oncology, a significant heterogeneity in model accuracy was observed, with GPT-4 showing performance competitive with a human benchmark. nejm.ai/4aJWOAY

In the most comprehensive head-to-head comparison of modern AI-based LLMs for application in oncology, a significant heterogeneity in model accuracy was observed, with GPT-4 showing performance competitive with a human benchmark. nejm.ai/4aJWOAY
UroToday.com (@urotoday) 's Twitter Profile Photo

Phase I trial investigates salvage SBRT, revealing promising biochemical control but highlighting significant moderate-grade toxicities. While early results are encouraging, optimal dosing and broader application remain under study > bit.ly/3MhNV6I Krishnan Patel, MD, MHS NIH

Phase I trial investigates salvage SBRT, revealing promising biochemical control but highlighting significant moderate-grade toxicities. While early results are encouraging, optimal dosing and broader application remain under study &gt; bit.ly/3MhNV6I <a href="/krishnan_patel/">Krishnan Patel, MD, MHS</a> <a href="/NIH/">NIH</a>
UroToday.com (@urotoday) 's Twitter Profile Photo

Phase I trial investigates salvage SBRT, revealing promising biochemical control but highlighting significant moderate-grade toxicities. While early results are encouraging, optimal dosing and broader application remain under study > bit.ly/3MhNV6I Krishnan Patel, MD, MHS NIH

Phase I trial investigates salvage SBRT, revealing promising biochemical control but highlighting significant moderate-grade toxicities. While early results are encouraging, optimal dosing and broader application remain under study &gt; bit.ly/3MhNV6I <a href="/krishnan_patel/">Krishnan Patel, MD, MHS</a> <a href="/NIH/">NIH</a>
Elai Davicioni (@davicioni) 's Twitter Profile Photo

Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncolo… pubmed.ncbi.nlm.nih.gov/39542826/ Krishnan Patel, MD, MHS NRG Oncology

Baris Turkbey MD (@radiolobt) 's Twitter Profile Photo

🎉Excited to share our new publication "Evaluating deep learning and radiologist performance in volumetric prostate cancer analysis with biparametric MRI and histopathologically mapped slides" 👏Huge congratulations to Enis C. Yilmaz, MD for leading this big project with our amazing team

🎉Excited to share our new publication "Evaluating deep learning and radiologist performance in volumetric prostate cancer analysis with biparametric MRI and histopathologically mapped slides" 
👏Huge congratulations to <a href="/eniscy/">Enis C. Yilmaz, MD</a> for leading this big project with our amazing team
Jeff Ryckman (@jryckman3) 's Twitter Profile Photo

🎉 Excited to share our latest work: RadOncCalc – A Mobile-Friendly Tool to Enhance Radiation Oncology Practice 📱⚛️ How does RadOncCalc help radiation oncologists save time and enhance patient care? Let’s break it down in this Tweetorial! practicalradonc.org/article/S1879-… 🧵👇

🎉 Excited to share our latest work: RadOncCalc – A Mobile-Friendly Tool to Enhance Radiation Oncology Practice 📱⚛️

How does RadOncCalc help radiation oncologists save time and enhance patient care? Let’s break it down in this Tweetorial! 

practicalradonc.org/article/S1879-…

🧵👇
ASTRO (@astro_org) 's Twitter Profile Photo

Does short-term ADT continue to show benefit after the negative results of NRG/RTOG 0815? Krishnan Patel, MD, MHS, Daniel E Spratt, Phuoc T. Tran, Daniel Krauss, Anthony D'Amico, and Paul Nguyen provide an up-to-date analysis suggesting continued benefit. tinyurl.com/redpatel

Does short-term ADT continue to show benefit after the negative results of NRG/RTOG 0815? <a href="/krishnan_patel/">Krishnan Patel, MD, MHS</a>, <a href="/DrSpratticus/">Daniel E Spratt</a>, <a href="/tranpt21/">Phuoc T. Tran</a>, Daniel Krauss, Anthony D'Amico, and <a href="/DrPaulNguyen/">Paul Nguyen</a> provide an up-to-date analysis suggesting continued benefit. tinyurl.com/redpatel
Baris Turkbey MD (@radiolobt) 's Twitter Profile Photo

2025 summary of our original research articles in #prostatecancer 🟢🟢🟢🟢🔵🟠🟡🟡🟡⚪️⚪️⚪️⚪️🟣🟣🟣🟣🟣🟣🟣🟣 (published=🟢, accepted=🔵, revision=🟠, under review=🟡, draft=⚪️, data analysis=🟣) #CancerResearch #AI #Radiology #TeamScience #Teamwork #ArtificialIntelligence

Krishnan Patel, MD, MHS (@krishnan_patel) 's Twitter Profile Photo

Check out our recent review on enhanced systemic therapy for localized prostate cancer now freely available: authors.elsevier.com/a/1lFrI3lXQoc1… A big thanks to our team (Melissa Abel, MD, Spyros Basourakos, Deborah Citrin) and Ravi (Ravi A Madan M.D.) for his leadership on this one!